Safety analysis of FOLFOX4 treatment in colorectal cancer patients: A comparison between two Asian studies and four western studies

Clinical Colorectal Cancer

Volumn 11, Issue 2, 2012, Pages 127-137

  Sugihara, Kenichi ^a   Ohtsu, Atsushi ^b   Shimada, Yasuhiro ^c   Mizunuma, Nobuyuki ^d   Lee, Po Huang ^e   De Gramont, Aimery ^f   Goldberg, Richard M ^g   Rothenberg, MacE L ^h   André, Thierry ⁱ   Brienza, Silvano ^j   Gomi, Katsushige ^k  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d CANCER INSTITUTE HOSPITAL   (Japan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f HÔPITAL SAINT ANTOINE   (France)

^g OHIO STATE UNIVERSITY   (United States)

^h VANDERBILT INGRAM CANCER CENTER   (United States)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j DEBIOPHARM SA   (Switzerland)

^k YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

more..

Author keywords

Colorectal cancer; Ethnic difference; FOLFOX4; Oxaliplatin; Safety

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; ASIAN; CANCER PATIENT; COLORECTAL CANCER; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL (TOPIC); DEMOGRAPHY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; RASH; SENSORY DYSFUNCTION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

EID: 84860783273     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.09.001     Document Type: Article

References (26)

1. J.M. Woynarowski, W.G. Chapman, C. Napier Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA Mol Pharmacol 54 1998 770 777 (Pubitemid 28523169)
2. S.G. Chaney, S.L. Campbell, E. Bassett Recognition and processing of cisplatin- and oxaliplatin-DNA adducts Critical Rev Oncol Hematol 53 2005 3 11 (Pubitemid 39656106)
3. E. Raymond, C. Buquet-Fagot, S. Djelloul Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers Anti-Cancer Drugs 8 1997 876 885 (Pubitemid 27487802)
4. A. de Gramont, A. Figer, M. Seymour Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938 2947 (Pubitemid 30644117)
5. R.M. Goldberg, D.J. Sargent, R.F. Morton A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 2004 23 30 (Pubitemid 41095110)
6. M.L. Rothenberg, A.M. Oza, R.H. Bigelow Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial J Clin Oncol 21 2003 2059 2069 (Pubitemid 46606353)
7. M.L. Rothenberg, A.M. Oza, B. Burger Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin Proc Am Soc Clin Oncol 22 Abstr 1011 2003
8. E.H. Lim, R.S.C. Lim, T.S. Wu Oxaliplatin/fluorouracil/leucovorin in advanced colorectal carcinoma: an Asian experience Ann Pharmacother 37 2003 1909 1912 (Pubitemid 37466593)
9. T.S. Yang, J.S. Chen, R. Tang Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study Chemotherapy 49 2003 194 199 (Pubitemid 36928695)
10. S.H. Park, J.Y. Sung, S.H. Han Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience Jpn J Clin Oncol 35 2005 531 535 (Pubitemid 41573943)
11. Y. Yamada, A. Ohtsu, N. Boku Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer Jpn J Clin Oncol 36 2006 218 223 (Pubitemid 43997321)
12. M. Suenaga, T. Nishina, I. Hyodo A feasibility study of oxaliplatin (L-OHP) in combination with infusional 5-FU/LV (FOLFOX4 regimen) for advanced colorectal cancer [in Japanese] Jpn J Cancer Chemother 35 2008 255 260
13. T. André, C. Boni, L. Mounedji-Boudiaf Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2004 2343 2351 (Pubitemid 38702845)
14. T. André, C. Boni, M. Navarro Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial J Clin Oncol 27 2009 3109 3116
15. P.H. Lee, Y.S. Park, J.F. Ji Safety and tolerability of FOLFOX4 in the adjuvant treatment of colon cancer in Asian patients: the MASCOT study Asia-Pac J Clin Oncol 5 2009 101 110
16. L.B. Saltz, S. Clarke, F. Diaz-Rubio Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
17. A. de Gramont, E. Van Cutsem, J. Tabernero AVANT: results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer Proc Am Soc Clin Oncol 29 Suppl 4 2011 (Abstr 362)
18. C. Bokemeyer, I. Bondarenko, A. Makhson Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2009 663 671
19. J.-Y. Douillard, S. Siena, J. Cassidy Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 2010 4697 4705
20. C.J. Allegra, G. Yothers, M.J. O'Connell Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer J Clin Oncol 27 2009 3385 3390
21. H.K. Sanoff, D.J. Sargent, E.M. Green Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial J Clin Oncol 27 2009 4109 4115
22. A.O. Laiyemo, C. Doubeni, P.F. Pinsky Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities J Natl Cancer Inst 102 2010 538 546
23. 105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy Clin Cancer Res 12 2006 3050 3056 (Pubitemid 43837350)
24. H.L. McLeod, D.J. Sargent, S. Marsh Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741 J Clin Oncol 28 2010 3227 3233
25. L. Gamelin, O. Capitain, A. Morel Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway Clin Cancer Res 13 2007 6359 6368 (Pubitemid 350075025)
26. D.G. Haller, J. Cassidy, S.J. Clarke Potential regional differences for the tolerability profiles of fluoropyrimidines J Clin Oncol 26 2008 2118 2123